A CpG-containing oligodeoxynucleotide adjuvant for acellular pertussis vaccine improves the protective response against Bordetella pertussis

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 2, 2013, Pages 325-331

  Asokanathan, Catpagavalli ^a   Corbel, Michael ^a   Xing, Dorothy ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Acellular pertussis vaccine; Adjuvant; Bordetella pertussis; CpG ODN

Indexed keywords

ALUMINUM HYDROXIDE; CHEMOKINE; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; HEMAGGLUTININ; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2A; NITRIC OXIDE; PERTACTIN; PERTUSSIS VACCINE; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 9; ACELLULAR VACCINE; ADHESIN; BACTERIUM ANTIBODY; BORDETELLA VIRULENCE FACTOR; CPG-OLIGONUCLEOTIDE; FILAMENTOUS HEMAGGLUTININ ADHESIN, BORDETELLA PERTUSSIS; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYRIBONUCLEOTIDE; OUTER MEMBRANE PROTEIN; PERTUSSIS TOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BORDETELLA PERTUSSIS; CONTROLLED STUDY; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; LIMIT OF DETECTION; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERTUSSIS; PILOT STUDY; TH1 CELL; ANIMAL; BLOOD; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM;

ADHESINS, BACTERIAL; ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ALUMINUM HYDROXIDE; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BORDETELLA PERTUSSIS; FEMALE; INJECTIONS, INTRAPERITONEAL; MACROPHAGES; MICE; NITRIC OXIDE; OLIGODEOXYRIBONUCLEOTIDES; PERTUSSIS TOXIN; PERTUSSIS VACCINE; VACCINES, ACELLULAR; VIRULENCE FACTORS, BORDETELLA;

EID: 84874675650     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.22755     Document Type: Article

References (35)

1. Greco D, Salmaso S, Mastrantonio P, Giuliano M, Tozzi AE, Anemona A, et al.; Progetto Pertosse Working Group. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 1996; 334:341-8; PMID:8538704; http://dx.doi.org/10.1056/NEJM199602083340601.
2. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996; 334:349-55; PMID:8538705; http://dx.doi.org/10.1056/NEJM199602083340602. (Pubitemid 26049587)
3. MacColl MR. How worried should we be about the whooping cough epidemic? The Weekend Australian Megazine 2012.
4. Stobbe M. CDC Whooping cough rising at alarming rate in US, Associated Press, http://news.yahoo. com/cdc-whooping-cough-rising-Alarming-rateus- 203023900.html 2012 Posted Jul 20.
5. Smith R. Five babies have died in biggest whooping cough outbreak for 20 years: HPA. The Telegraph, July 2012.
6. Ausiello CM, Urbani F, la Sala A, Lande R, Cassone A. Vaccine-And antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infect Immun 1997; 65:2168-74; PMID:9169747. (Pubitemid 27237293)
7. Mascart F, Hainaut M, Peltier A, Verscheure V, Levy J, Locht C. Modulation of the infant immune responses by the first pertussis vaccine administrations. Vaccine 2007; 25:391-8; PMID:17116347; http://dx.doi.org/10. 1016/j.vaccine.2006.06.046. (Pubitemid 44873143)
8. Gupta RK. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev 1998; 32:155-72; PMID:10837642; http://dx.doi.org/10.1016/S0169-409X(98)00008-8. (Pubitemid 28267407)
9. Canthaboo C, Williams L, Xing DKL, Corbel MJ. Investigation of cellular and humoral immune responses to whole cell and acellular pertussis vaccines. Vaccine 2000; 19:637-43; PMID:11090715; http://dx.doi.org/10.1016/S0264-410X(00) 00253-X.
10. Klinman DM, Klaschik S, Sato T, Tross D. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Adv Drug Deliv Rev 2009; 61:248-55; PMID:19272313; http://dx.doi.org/10.1016/j.addr.2008.12.012.
11. Kreig AM. Immune effects and mechanisms of action of CpG motifs. Vaccine 2001 19:618-22; http://dx.doi.org/10.1016/S0264-410X(00)00249-8.
12. McCluskie MJ, Davis HL. CpG DNA as mucosal adjuvant. Vaccine 1999; 18:231-7; PMID:10506647; http://dx.doi.org/10.1016/S0264-410X(99)00194-2. (Pubitemid 29443996)
13. McCluskie MJ, Weeratna RD, Davis HL. The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants. Vaccine 2001; 19:2657-60; PMID:11257405; http://dx.doi.org/10.1016/S0264-410X(00)00496-5. (Pubitemid 32234285)
14. Ghosh DK, Misukonis MA, Reich C, Pisetsky DS, Weinberg JB. Host response to infection: the role of CpG DNA in induction of cyclooxygenase 2 and nitric oxide synthase 2 in murine macrophages. Infect Immun 2001; 69:7703-10; PMID:11705951; http://dx.doi.org/10.1128/IAI.69.12.7703-7710.2001. (Pubitemid 33086600)
15. Weeratna RD, McCluskie MJ, Xu Y, Davis HL. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 2000; 18:1755-62; PMID:10699323; http://dx.doi.org/10.1016/S0264-410X(99)00526-5. (Pubitemid 30122837)
16. Sugai T, Mori M, Nakazawa M, Ichino M, Naruto T, Kobayashi N, et al. A CpG-containing oligodeoxynucleotide as an efficient adjuvant counterbalancing the Th1/Th2 immune response in diphtheriatetanus-pertussis vaccine. Vaccine 2005; 23:5450-6; PMID:16006019; http://dx.doi.org/10.1016/j.vaccine.2004.09.041. (Pubitemid 41579318)
17. Gracia A, Polewicz M, Halperin SA, Hancock RE, Potter AA, Babiuk LA, et al. Antibody responses in adult and neonatal BALB/c mice to immunization with novel Bordetella pertussis vaccine formulations. Vaccine 2011; 29:1595-604; PMID:21215343; http://dx.doi.org/10.1016/j.vaccine.2010.12.083.
18. Garlapati S, Eng NF, Kiros TG, Kindrachuk J, Mutwiri GK, Hancock RE, et al. Immunization with PCEP microparticles containing pertussis toxoid, CpG ODN and a synthetic innate defense regulator peptide induces protective immunity against pertussis. Vaccine 2011; 29:6540-8; PMID:21771625; http://dx.doi.org/10. 1016/j.vaccine.2011.07.009.
19. Canthaboo C, Xing D, Wei XQ, Corbel MJ. Investigation of role of nitric oxide in protection from Bordetella pertussis respiratory challenge. Infect Immun 2002; 70:679-84; PMID:11796599; http://dx.doi.org/10.1128/IAI.70.2.679- 684.2002. (Pubitemid 34083828)
20. Xing DKL, Canthaboo C, Corbel MJ. Effect of pertussis toxin on the induction of nitric oxide synthesis in murine macrophages and on protection in vivo. Vaccine 2000; 18:2110-9; PMID:10715525; http://dx.doi.org/10.1016/S0264- 410X(99)00562-9. (Pubitemid 30129100)
21. Rankin R, Pontarollo R, Gomis S, Karvonen B, Willson P, Loehr BI, et al. CpG-containing oligodeoxynucleotides augment and switch the immune responses of cattle to bovine herpesvirus-1 glycoprotein D. Vaccine 2002; 20:3014-22; PMID:12126915; http://dx.doi.org/10.1016/S0264-410X(02)00216-5. (Pubitemid 34785973)
22. Linghua Z, Xingshan T, Fengzhen Z. The efficacy of CpG oligodinucleotides, in combination with conventional adjuvants, as immunological adjuvants to swine streptococcic septicemia vaccine in piglets in vivo. Int Immunopharmacol 2006; 6:1267-76; PMID:16782539; http://dx.doi.org/10.1016/j. intimp.2006.03.009. (Pubitemid 43868187)
23. Klinman DM, Klaschik S, Tomaru K, Shirota H, Tross D, Ikeuchi H. Immunostimulatory CpG oligonucleotides: Effect on gene expression and utility as vaccine adjuvants. Vaccine 2010; 28:1919-23; PMID:20188247; http://dx.doi.org/10.1016/j.vaccine.2009.10.094.
24. Cox JC, Coulter AR. Adjuvants-A classification and review of their modes of action. Vaccine 1997; 15:248-56; PMID:9139482; http://dx.doi.org/10.1016/ S0264-410X(96)00183-1. (Pubitemid 27116125)
25. Wang W, Singh M. Selection of adjuvants for enhanced vaccine potency. World Journal of Vaccine 2011 1:1-40.
26. Morefield GL, Sokolovska A, Jiang D. HogenEsch H, Robinson JP, Hem SL. Role of aluminium-containing adjuvants in antigen internalisation by dendritic cells in vitro. Vaccine 2005; 23:1588-95; PMID:15694511; http://dx.doi.org/10. 1016/j.vaccine.2004.07.050. (Pubitemid 40203396)
27. Aebig JA, Mullen GED, Dobrescu G, Rausch K, Lambert L, Ajose-Popoola O, et al. Formulation of vaccines containing CpG oligonucleotides and alum. J Immunol Methods 2007; 323:139-46; PMID:17512533; http://dx.doi.org/10.1016/j. jim.2007.04.003. (Pubitemid 46890965)
28. McCluskie MJ, Davis HL. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol 1998 161:4463-6; PMID:9794366. (Pubitemid 28492011)
29. Horner AA, Ronaghy A, Cheng PM, Nguyen MD, Cho HJ, Broide D, et al. Immunostimulatory DNA is a potent mucosal adjuvant. Cell Immunol 1998; 190:77-82; PMID:9826449; http://dx.doi.org/10.1006/cimm.1998.1400. (Pubitemid 28550865)
30. Moldoveanu Z, Love-Homan L, Huang WQ, Krieg AM. CpG DNA, a novel immune enhancer for systemic and mucosal immunisation with influenza virus. Vaccine 1998 16:121; http://dx.doi.org/10.1016/S0264-410X(98)80122-9. (Pubitemid 28307893)
31. Xing DKL, Canthaboo C, Corbel MJ. Nitric oxide induction in murine macrophages and spleen cells by whole-cell Bordetella pertussis vaccine. Vaccine 1998; 16:16-23; PMID:9607004; http://dx.doi.org/10.1016/S0264-410X(97)00157-6. (Pubitemid 27504799)
32. Mills KHG, Barnard A, Watkins J, Redhead K. Cellmediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect Immun 1993 61:399-410; PMID:8423070. (Pubitemid 23030823)
33. Higgs R, Higgins SC, Ross PJ, Mills KHG Immunity to the respiratory pathogen Bordetella pertussis Natue publishing group, Mucosa Immunology 2012 doi 10.1038/mi.2012.54
34. Mills KH, Ryan M, Ryan E, Mahon BP. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect Immun 1998; 66:594-602; PMID:9453614. (Pubitemid 28074200)
35. Xing DKL, Das RG, Williams L, Canthaboo C, Tremmil J, Corbel MJ. An aerosol challenge model of Bordetella pertussis infection as a potential bioassay for acellular pertussis vaccines. Vaccine 1999; 17:565-76; PMID:10075163; http://dx.doi.org/10.1016/S0264-410X(98)00235-7. (Pubitemid 29071088)